Genocea Biosciences, Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 72 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Genocea Biosciences
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GNCA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Genocea Biosciences stock price (NASDAQ: GNCA)Use our graph to track the performance of GNCA stocks over time.
Genocea Biosciences shares at a glance
|Latest market close||$2.36|
|52-week range||$1.80 - $5.75|
|50-day moving average||$2.28|
|200-day moving average||$2.62|
|Wall St. target price||$6.68|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.38|
Buy Genocea Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Genocea Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genocea Biosciences price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||3.06%|
|3 months (2021-04-29)||-11.28%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Genocea Biosciences financials
|Revenue TTM||$1.4 million|
|Gross profit TTM||$1.4 million|
|Return on assets TTM||-44.56%|
|Return on equity TTM||-579.95%|
|Market capitalisation||$112.7 million|
TTM: trailing 12 months
Shorting Genocea Biosciences shares
There are currently 1.5 million Genocea Biosciences shares held short by investors – that's known as Genocea Biosciences's "short interest". This figure is 2.1% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Genocea Biosciences shares can be evaluated.
Genocea Biosciences's "short interest ratio" (SIR)
Genocea Biosciences's "short interest ratio" (SIR) is the quantity of Genocea Biosciences shares currently shorted divided by the average quantity of Genocea Biosciences shares traded daily (recently around 303083.96039604). Genocea Biosciences's SIR currently stands at 5.05. In other words for every 100,000 Genocea Biosciences shares traded daily on the market, roughly 5050 shares are currently held short.
However Genocea Biosciences's short interest can also be evaluated against the total number of Genocea Biosciences shares, or, against the total number of tradable Genocea Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genocea Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Genocea Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0559% of the tradable shares (for every 100,000 tradable Genocea Biosciences shares, roughly 56 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Genocea Biosciences.
Find out more about how you can short Genocea Biosciences stock.
Genocea Biosciences share dividends
We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.
Have Genocea Biosciences's shares ever split?
Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.
Genocea Biosciences share price volatility
Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $1.8 up to $5.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.624. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genocea Biosciences overview
Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. .
Stocks similar to Genocea Biosciences
Genocea Biosciences in the news
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
Frequently asked questionsWhat percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 8.864% of Genocea Biosciences shares are held by insiders and 59.155% by institutions. How many people work for Genocea Biosciences?
Latest data suggests 72 work at Genocea Biosciences. When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December. Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140 What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010 What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427104
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert